Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT-814 in menopausal women with moderate to severe vasomotor symptoms
2018-002763-26Phase 2Completed
- Sponsor
- NeRRe Therapeutics
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elinzanetant in menopause and hot flash (5 arms), sponsored by NeRRe Therapeutics. Started Oct 2018; status: completed.
02
Drugs
elinzanetant
03
Conditions
menopausehot flash
Beyond the preview
Go deeper on 2018-002763-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002763-26.